NYSE
BIO

Bio-Rad Laboratories, Inc.

Shareholder Derivative Litigation

Rigrodsky & Long, P.A. Announces an Investigation into Possible Breaches of Fiduciary Duties by the Board of Directors of Bio-Rad Laboratories, Inc. (NYSE: BIO)

Rigrodsky & Long, P.A. announces that it is investigating whether certain officers and directors of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) (NYSE: BIO) breached their fiduciary duties to shareholders.

On November 3, 2014, Bio-Rad announced the full resolution of previously disclosed investigations by the U.S. Department of Justice (“DOJ”) and Securities and Exchange Commission (“SEC”) into past violations of the Foreign Corrupt Practices Act (“FCPA”) that occurred from 2005 to 2010 related to Thailand, Vietnam, and Russia.

Although the DOJ declined to prosecute Bio-Rad, the parties entered into a Non-Prosecution Agreement under which Bio-Rad has agreed to pay a penalty of $14.35 million.  Under the terms of the civil settlement with the SEC, the Company will pay $40.7 million in disgorgement and prejudgment interest.  The Company has also agreed to certain future reporting, compliance and self-monitoring provisions over the next two years.

If you own the common stock of Bio-Rad and would like to learn more about the investigation, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.